- Conditions
- Leukemia
- Interventions
- 3 Day Thiarabine, 5 Day Thiarabine
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 16 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1393–1416
of 2,419
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Leukemia, Lymphoma
- Interventions
- rituximab, pentostatin
- Biological · Drug
- Lead sponsor
- Pharmatech Oncology
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2003
- U.S. locations
- 5
- States / cities
- Rancho Mirage, California • Redding, California • Clinton, Maryland + 2 more
- Conditions
- Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndrome, Essential Thrombocythemia, Myeloproliferative Neoplasm, Paroxysmal Nocturnal Hemoglobinuria, Polycythemia Vera, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Primary Myelofibrosis, Refractory Anemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Ring Sideroblasts, Refractory Cytopenia With Multilineage Dysplasia, Refractory Cytopenia With Multilineage Dysplasia and Ring Sideroblasts
- Interventions
- Cyclosporine, Fludarabine Phosphate, Laboratory Biomarker Analysis, Mycophenolate Mofetil, Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation, Total-Body Irradiation
- Drug · Other · Procedure + 1 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 50 Years to 75 Years
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2018
- U.S. locations
- 3
- States / cities
- Salt Lake City, Utah • Seattle, Washington
- Conditions
- Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- penclomedine
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1997
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Leukemia
- Interventions
- alemtuzumab, filgrastim, cyclophosphamide, peripheral blood stem cell transplantation, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2001
- U.S. locations
- 14
- States / cities
- Chicago, Illinois • Baltimore, Maryland • Boston, Massachusetts + 8 more
- Conditions
- Leukemia, Lymphocytic, Chronic, B-Cell, Chronic Lymphocytic Leukemia, Lymphoma, Small Lymphocytic
- Interventions
- Lenalidomide, Rituximab, and Cyclophosphamide
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2010
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Interventions
- Obinutuzumab, ABBV-453
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 6
- States / cities
- Duarte, California • Irvine, California • Billings, Montana + 3 more
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Interventions
- Acalabrutinib, Obinutuzumab
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 8
- States / cities
- Basking Ridge, New Jersey • Hackensack, New Jersey • Middletown, New Jersey + 5 more
- Conditions
- Chronic Lymphocytic Leukemia, CLL
- Interventions
- Revlimid, Rituximab
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2022
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Chronic Lymphocytic Leukemia (CLL), Waldenstrom Macroglobulinemia (WM)
- Interventions
- Shingrix vaccine
- Drug
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Richter Syndrome, Chronic Lymphocytic Leukemia
- Interventions
- Polatuzumab Vedotin, Rituximab, Etoposide, Prednisone, Cyclophosphamide, Hydroxydaunomycin
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 4
- States / cities
- New York, New York • Columbus, Ohio
- Conditions
- Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), Chronic Lymphocytic Leukemia in Relapse, Small Lymphocytic Lymphoma, Relapsed, Waldenstrom's Macroglobulinemia Recurrent, Follicular B-cell Non-Hodgkin's Lymphoma, B-cell Lymphoma Refractory, Mantle Cell Lymphoma Recurrent, Hairy Cell Leukemia, Diffuse Large B Cell Lymphoma, Waldenstrom's Macroglobulinemia Refractory, Mantle Cell Lymphoma Refractory
- Interventions
- Prior MB-102 CAR-T cell investigational product., Prior MB-106 CAR-T cell investigational product.
- Biological
- Lead sponsor
- Mustang Bio
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 5
- States / cities
- Orange, California • Boston, Massachusetts • Rochester, New York + 2 more
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Myeloid Leukemia in Remission, Adult Erythroleukemia (M6a), Adult Nasal Type Extranodal NK/T-cell Lymphoma, Adult Pure Erythroid Leukemia (M6b), Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Blastic Phase Chronic Myelogenous Leukemia, Childhood Acute Erythroleukemia (M6), Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Megakaryocytic Leukemia (M7), Childhood Acute Myeloid Leukemia in Remission, Childhood Burkitt Lymphoma, Childhood Chronic Myelogenous Leukemia, Childhood Diffuse Large Cell Lymphoma, Childhood Immunoblastic Large Cell Lymphoma, Childhood Myelodysplastic Syndromes, Childhood Nasal Type Extranodal NK/T-cell Lymphoma, Chronic Myelomonocytic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, Cutaneous B-cell Non-Hodgkin Lymphoma, de Novo Myelodysplastic Syndromes, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hepatosplenic T-cell Lymphoma, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Noncutaneous Extranodal Lymphoma, Peripheral T-cell Lymphoma, Philadelphia Chromosome Negative Chronic Myelogenous Leukemia, Post-transplant Lymphoproliferative Disorder, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Childhood Grade III Lymphomatoid Granulomatosis, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Recurrent/Refractory Childhood Hodgkin Lymphoma, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Stage III Multiple Myeloma, Testicular Lymphoma, Waldenström Macroglobulinemia
- Interventions
- cyclophosphamide, cyclosporine, peripheral blood stem cell transplantation, total-body irradiation, fludarabine phosphate, busulfan, allogeneic hematopoietic stem cell transplantation
- Drug · Procedure · Radiation
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- Up to 65 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- Biospecimen Collection
- Other
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2015
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma, Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Interventions
- umbilical cord blood transplantation, Allopurinol, fludarabine phosphate, Cyclophosphamide, Total body irradiation, Treg infusion, Sirolimus
- Biological · Drug · Radiation
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2015
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Juvenile Myelomonocytic Leukemia, Recurrent Acute Biphenotypic Leukemia, Recurrent Acute Undifferentiated Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia, Refractory Adult Acute Lymphoblastic Leukemia, Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm, Recurrent Myelodysplastic Syndrome, Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm, Refractory Myelodysplastic Syndrome, Acute Undifferentiated Leukemia, Mixed Phenotype Acute Leukemia, Recurrent Chronic Myeloid Leukemia, BCR-ABL1 Positive, Refractory Chronic Myeloid Leukemia, BCR-ABL1 Positive, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Acute Biphenotypic Leukemia, Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Minimal Residual Disease, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Leukemia, Chronic Myeloid Leukemia, BCR-ABL1 Positive
- Interventions
- CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR, Bone Marrow Aspiration, Biospecimen Collection
- Biological · Procedure
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- Up to 80 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2028
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Myelogenous Leukemia, Chronic, Chronic Phase
- Interventions
- Gleevec
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 15 Years and older
- Enrollment
- 117 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2013
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Small Lymphocytic Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Small Lymphocytic Lymphoma
- Interventions
- cyclophosphamide, fludarabine phosphate, vincristine sulfate, prednisone, rituximab, laboratory biomarker analysis
- Drug · Biological · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 515 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1998
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission, Chronic Lymphocytic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Cytomegaloviral Infection, Hodgkin Lymphoma, Lymphadenopathy, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, Myelofibrosis, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma
- Interventions
- Laboratory Biomarker Analysis, Multi-peptide CMV-Modified Vaccinia Ankara Vaccine, Placebo
- Other · Biological
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2027
- U.S. locations
- 3
- States / cities
- Duarte, California • Boston, Massachusetts • Houston, Texas
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- GX15-070MS
- Drug
- Lead sponsor
- Gemin X
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 4
- States / cities
- La Jolla, California • Washington D.C., District of Columbia • Hershey, Pennsylvania + 1 more
- Conditions
- Leukemia
- Interventions
- Alemtuzumab, Rituximab
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2011
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- Cyclophosphamide, Fludarabine, Sargramostim, Rituximab
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2014
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia, Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Chronic Lymphocytic Leukemia
- Interventions
- allogeneic cytomegalovirus-specific cytotoxic T lymphocytes
- Biological
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Myeloid Neoplasm
- Interventions
- CPX-351, MHA, Allogeneic Hematopoietic Stem Cell Transplantation
- Drug · Procedure
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee